Brief: Metacrine Presents Positive Met409 Phase 1B Clinical Data In Nash Patients At The Digital International Liver Congress 2020

Metacrine

27/08/2020 12:55

Aug 27 (Reuters) - Metacrine Inc  MTCR.O :
    * METACRINE PRESENTS POSITIVE MET409 PHASE 1B CLINICAL DATA
IN
NASH PATIENTS AT THE DIGITAL INTERNATIONAL LIVER CONGRESS™ 2020
    * METACRINE - IN STUDY, MET409 LOWERED LIVER FAT CONTENT,
WITH
MEAN RELATIVE REDUCTIONS OF 55% IN 80 MG COHORT, 38% IN 50 MG
COHORT, VERSUS 6% IN PLACEBO
    * METACRINE INC - MET409 WAS GENERALLY WELL-TOLERATED IN
PATIENTS
TREATED, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS
REPORTED

Source text for Eikon:  ID:nGNXbJyV4R 
Further company coverage:  MTCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))